leadf
logo-loader
view4D pharma plc

4D restarts Thetanix phase I trials

The firm has been given permission to restart clinical trials on its Crohn’s Disease treatment, Thtetanix, after a four-month delay

test tubes in a laboratory
4D can now restart its Thetanix phase I trials after approval from the MHRA

Pharmaceutical company 4D Pharma PLC (LON:DDDD) has restarted phase I clinical trials of its paediatric Crohn’s Disease treatment Thetanix.

The trial was supposed to begin dosing on 1 March but had been delayed as a precaution due to quality concerns that came to light at one of the company’s suppliers during the manufacture of a batch of Thetanix.

The biotherapeutics firm has now received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the clinical study to be restarted.

4D has also completed its own investigation into the matter but gave no further details.

Thetanix is 4D’s proprietary programme for the treatment of Crohn’s Disease, a chronic bowel disease that causes inflammation and swelling across the lining of the digestive tract.

Shares were down 7.5p, or 0.9%, to 850p.

Quick facts: 4D pharma plc

Price: 160 GBX

LSE:DDDD
Market: LSE
Market Cap: £210.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read